TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
Brief Summary: This study aims to evaluate, in a randomized controlled trial, tobacco treatments of varying intensities for smokers hospitalized on acute psychiatric inpatient units.


Options:
A: Arm Label: 0.8 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.26 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.12 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.07 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.03 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.04 mg nicotine with 13 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: Usual brand; Type: OTHER; Interventions: Other: very low nicotine content cigarettes | Intervention Type: OTHER; Name: very low nicotine content cigarettes; Assigned to Arm(s): 0.03 mg nicotine with 9 mg tar, 0.04 mg nicotine with 13 mg tar, 0.07 mg nicotine with 9 mg tar, 0.12 mg nicotine with 9 mg tar, 0.26 mg nicotine with 9 mg tar, 0.8 mg nicotine with 9 mg tar, Usual brand
B: Arm Label: Assessment Only (ASSESS); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Generic Self-Help (GENERIC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: GENERIC | Arm Label: Targeted Self-Help (eTARGET); Type: EXPERIMENTAL; Interventions: Behavioral: eTARGET | Intervention Type: BEHAVIORAL; Name: GENERIC; Assigned to Arm(s): Generic Self-Help (GENERIC) | Intervention Type: BEHAVIORAL; Name: eTARGET; Assigned to Arm(s): Targeted Self-Help (eTARGET)
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Brief Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: Extended Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Extended Treatment | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): Brief Treatment | Intervention Type: BEHAVIORAL; Name: Extended Treatment; Assigned to Arm(s): Extended Treatment | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
Brief Summary: This study aims to evaluate, in a randomized controlled trial, tobacco treatments of varying intensities for smokers hospitalized on acute psychiatric inpatient units.


Options:
A: Arm Label: E-cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Traditional cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Mixed group; Type: N/A; Interventions: N/A
B: Arm Label: EGO/CE4, 9mg nicotine; Type: OTHER; Interventions: Device: EGO/CE4, 9mg nicotine | Intervention Type: DEVICE; Name: EGO/CE4, 9mg nicotine; Assigned to Arm(s): EGO/CE4, 9mg nicotine
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Brief Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: Extended Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Extended Treatment | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): Brief Treatment | Intervention Type: BEHAVIORAL; Name: Extended Treatment; Assigned to Arm(s): Extended Treatment | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Arm Label: E-cigarette free access; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette free access | Arm Label: E-cigarette/NRT/Zyban/Chantix Choice; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette/NRT/Zyban/Chantix Choice | Arm Label: Outcome Incentive arm; Type: EXPERIMENTAL; Interventions: Behavioral: Outcome Incentive arm | Arm Label: Loss framing incentive arm; Type: EXPERIMENTAL; Interventions: Behavioral: Loss framing incentive arm | Intervention Type: BEHAVIORAL; Name: E-cigarette free access; Assigned to Arm(s): E-cigarette free access | Intervention Type: BEHAVIORAL; Name: E-cigarette/NRT/Zyban/Chantix Choice; Assigned to Arm(s): E-cigarette/NRT/Zyban/Chantix Choice | Intervention Type: BEHAVIORAL; Name: Outcome Incentive arm; Assigned to Arm(s): Outcome Incentive arm | Intervention Type: BEHAVIORAL; Name: Loss framing incentive arm; Assigned to Arm(s): Loss framing incentive arm | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
Brief Summary: This study aims to evaluate, in a randomized controlled trial, tobacco treatments of varying intensities for smokers hospitalized on acute psychiatric inpatient units.


Options:
A: Arm Label: cigarette substitute; Type: EXPERIMENTAL; Interventions: Other: cigarette substitute | Arm Label: e-cigarette (with 0 mg/ml nicotine); Type: EXPERIMENTAL; Interventions: Other: e-cigarette | Arm Label: e-cigarette (with 8 mg/ml nicotine); Type: EXPERIMENTAL; Interventions: Other: e-cigarette | Arm Label: e-cigarette (with 36 mg/ml nicotine); Type: EXPERIMENTAL; Interventions: Other: e-cigarette | Intervention Type: OTHER; Name: e-cigarette; Assigned to Arm(s): e-cigarette (with 0 mg/ml nicotine), e-cigarette (with 36 mg/ml nicotine), e-cigarette (with 8 mg/ml nicotine) | Intervention Type: OTHER; Name: cigarette substitute; Assigned to Arm(s): cigarette substitute
B: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator
C: Arm Label: HIGH NICOTINE; Type: N/A; Interventions: N/A
D: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Brief Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: Extended Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Extended Treatment | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): Brief Treatment | Intervention Type: BEHAVIORAL; Name: Extended Treatment; Assigned to Arm(s): Extended Treatment | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
Brief Summary: This study aims to evaluate, in a randomized controlled trial, tobacco treatments of varying intensities for smokers hospitalized on acute psychiatric inpatient units.


Options:
A: Arm Label: PRO+NRT+TC; Type: EXPERIMENTAL; Interventions: Other: proactive outreach (PRO), Other: telephone counseling (TC), Other: Nicotine replacement therapy (NRT) | Arm Label: Usual Care (UC); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care (UC) | Intervention Type: OTHER; Name: proactive outreach (PRO); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: telephone counseling (TC); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: Nicotine replacement therapy (NRT); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: Usual care (UC); Assigned to Arm(s): Usual Care (UC)
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Brief Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: Extended Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Extended Treatment | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): Brief Treatment | Intervention Type: BEHAVIORAL; Name: Extended Treatment; Assigned to Arm(s): Extended Treatment | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Counseling | Intervention Type: BEHAVIORAL; Name: Lifestyle Counseling; Assigned to Arm(s): Lifestyle Counseling
D: Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Nicotine Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Brief Hospital Counseling | Arm Label: Telephone Counseling + Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Brief hospital counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Hospital Counseling | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Nicotine Patches, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Telephone Counseling, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Brief Hospital Counseling; Assigned to Arm(s): Brief hospital counseling, Nicotine Patches, Telephone Counseling, Telephone Counseling + Patches

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous MEDI-528 in Adults With Uncontrolled Asthma
Brief Summary: To study the effectiveness and safety of multiple-doses of MEDI-528 on asthma control in adult participants with uncontrolled, moderate-to-severe, persistent asthma.


Options:
A: Arm Label: AMG 317 75 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 75 mg | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: AMG 317 300 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 300 mg | Arm Label: AMG 317 150 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 75 mg; Assigned to Arm(s): AMG 317 75 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 150 mg; Assigned to Arm(s): AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 300 mg; Assigned to Arm(s): AMG 317 300 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Arm
B: Arm Label: MEDI528 30 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 30 mg | Arm Label: MEDI528 100 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 100 mg | Arm Label: MEDI528 300 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 300 mg | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI528 30 mg; Assigned to Arm(s): MEDI528 30 mg | Intervention Type: BIOLOGICAL; Name: MEDI528 100 mg; Assigned to Arm(s): MEDI528 100 mg | Intervention Type: BIOLOGICAL; Name: MEDI528 300 mg; Assigned to Arm(s): MEDI528 300 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Mepolizumab IV; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab IV, Drug: SC Placebo | Arm Label: Mepolizumab SC; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab SC, Drug: IV Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo, Drug: SC Placebo | Intervention Type: DRUG; Name: Mepolizumab IV; Assigned to Arm(s): Mepolizumab IV | Intervention Type: DRUG; Name: Mepolizumab SC; Assigned to Arm(s): Mepolizumab SC | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): Mepolizumab SC, Placebo | Intervention Type: DRUG; Name: SC Placebo; Assigned to Arm(s): Mepolizumab IV, Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: CAT-354 150 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 150 mg | Arm Label: CAT-354 300 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 300 mg | Arm Label: CAT-354 600 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 600 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 150 mg; Assigned to Arm(s): CAT-354 150 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 300 mg; Assigned to Arm(s): CAT-354 300 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 600 mg; Assigned to Arm(s): CAT-354 600 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Brief Summary: The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.


Options:
A: Arm Label: Rosiglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosiglitazone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Rosiglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Linagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Alogliptin; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin | Intervention Type: DRUG; Name: Alogliptin; Assigned to Arm(s): Alogliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Brief Summary: The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal Saline | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: OTHER; Name: Normal Saline; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Alogliptin; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin | Intervention Type: DRUG; Name: Alogliptin; Assigned to Arm(s): Alogliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Sitagliptin 25 mg, Drug: Placebo for Sitagliptin 50 mg | Arm Label: Sitagliptin 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo for Sitagliptin 50 mg, Drug: Sitagliptin 25 mg | Arm Label: Sitagliptin 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo for Sitagliptin 25 mg, Drug: Sitagliptin 50 mg | Intervention Type: DRUG; Name: Placebo for Sitagliptin 25 mg; Assigned to Arm(s): Placebo, Sitagliptin 50 mg | Intervention Type: DRUG; Name: Placebo for Sitagliptin 50 mg; Assigned to Arm(s): Placebo, Sitagliptin 25 mg | Intervention Type: DRUG; Name: Sitagliptin 25 mg; Assigned to Arm(s): Sitagliptin 25 mg | Intervention Type: DRUG; Name: Sitagliptin 50 mg; Assigned to Arm(s): Sitagliptin 50 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
Brief Summary: The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.


Options:
A: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 low dose, Drug: Placebo BI 10773 high dose | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 high dose, Drug: Placebo BI 10773 low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo BI 10773 high dose, Drug: Placebo BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773 low dose; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773 high dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): BI 10773 low dose
B: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Alogliptin; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin | Intervention Type: DRUG; Name: Alogliptin; Assigned to Arm(s): Alogliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial
Brief Summary: The primary goal of this study is to determine the clinical advantage of pre-treatment with mifepristone in second trimester misoprostol induction abortion. This will be a randomized controlled double-blinded trial of 120 women in each country comparing misoprostol alone to mifepristone plus misoprostol for second trimester (14-21 weeks' LMP) medical abortion.


Options:
A: Arm Label: 17 alfa hydroxy Progesterone caproate; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17 alpha-hydroxy progesterone caproate | Arm Label: Micronized Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: micronized Progesterone | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Control | Intervention Type: DRUG; Name: 17 alpha-hydroxy progesterone caproate; Assigned to Arm(s): 17 alfa hydroxy Progesterone caproate | Intervention Type: DRUG; Name: micronized Progesterone; Assigned to Arm(s): Micronized Progesterone | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control
B: Arm Label: mifepristone+misoprostol; Type: EXPERIMENTAL; Interventions: Drug: mifepristone+misoprostol | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol+placebo | Intervention Type: DRUG; Name: mifepristone+misoprostol; Assigned to Arm(s): mifepristone+misoprostol | Intervention Type: DRUG; Name: misoprostol+placebo; Assigned to Arm(s): misoprostol
C: Arm Label: Dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dydrogesterone | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dydrogesterone; Assigned to Arm(s): Dydrogesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo pill
D: Arm Label: Lipoic acid; Type: EXPERIMENTAL; Interventions: Device: Lipoic acid | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DEVICE; Name: Lipoic acid; Assigned to Arm(s): Lipoic acid | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone

Answer: B